Compare PCRX & ETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | ETD |
|---|---|---|
| Founded | 2006 | 1932 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Home Furnishings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 610.5M |
| IPO Year | 2011 | 1993 |
| Metric | PCRX | ETD |
|---|---|---|
| Price | $19.35 | $24.17 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $35.33 | $28.00 |
| AVG Volume (30 Days) | ★ 1.0M | 293.2K |
| Earning Date | 02-26-2026 | 01-28-2026 |
| Dividend Yield | N/A | ★ 7.34% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.47 | ★ 1.85 |
| Revenue | ★ $716,791,000.00 | $607,296,000.00 |
| Revenue This Year | $6.21 | N/A |
| Revenue Next Year | $8.26 | $3.32 |
| P/E Ratio | $40.65 | ★ $13.33 |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $18.92 | $21.67 |
| 52 Week High | $27.64 | $32.61 |
| Indicator | PCRX | ETD |
|---|---|---|
| Relative Strength Index (RSI) | 27.05 | 52.88 |
| Support Level | $22.52 | $23.99 |
| Resistance Level | $22.56 | $24.87 |
| Average True Range (ATR) | 1.33 | 0.58 |
| MACD | -0.75 | 0.16 |
| Stochastic Oscillator | 6.80 | 67.89 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.